Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is 1.3x normal with puts leading calls 8:5. Implied volatility suggests the market is anticipating a move near 17.7%, or $1.55, after results are released. Median move over the past eight quarters is 6.0%.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals options imply 12.0% move in share price post-earnings
- Is CRVS a Buy, Before Earnings?
- Corvus Pharmaceuticals upgraded to Outperform from Neutral at Mizuho
- Biotech Alert: Searches spiking for these stocks today
- Corvus Pharmaceuticals price target raised to $21 from $12 at Ladenburg